EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last October, expects to report full topline results in the first quarter of 2025.
VERONA is a phase II trial evaluating the company's lead investigational product Duravyu in diabetic macular edema patients previously treated with a standard-of-care FDA-approved anti-VEGF treatment, like intravitreal Aflibercept. Duravyu delivers Vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), formulated in a solid bioerodible insert using EyePoint's proprietary sustained-release Durasert E technology.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com